Drugs / Varicella Zoster Vaccine
Varicella Zoster Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00007501 | Nov 1998 → Apr 2004 | herpes zoster, postherpetic neuralgia | US Department of Veterans Affairs | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT02408159 | Jun 2016 → Jan 2017 | psoriasis | Innovaderm Research Inc. | Terminated | No outcome recorded Stop: Enrollment |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2013-10-23 | Merck Sharp & Dohme LLC | ZOSTAVAX® (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product merck.com ↗ |
| 2012-04-02 | Merck Sharp & Dohme LLC | Efficacy and Safety Data for ZOSTAVAX® (Zoster Vaccine Live), Merck’s Shingles Vaccine, in Adults Ages 50 to 59 Published in Clinical Infectious Diseases merck.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Varicella-zoster vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00007501 ↗ |
| Known as | Oka/Merck VZV vaccine | “investigational live attenuated Oka/Merck VZV vaccine ("zoster vaccine")” PMID 15930418 ↗ Jun 2005 |
| Known as | zoster vaccine | “investigational live attenuated Oka/Merck VZV vaccine ("zoster vaccine")” PMID 15930418 ↗ Jun 2005 |
| Modality | Vaccine | “investigational live attenuated Oka/Merck VZV vaccine ("zoster vaccine")” PMID 15930418 ↗ Jun 2005 |